The aim of this study was to use meta-analysis to combine the results of numerous studies and examine the impact of heparin-bonded circuits on clinical outcomes and the resulting costs. Heparin-bonded circuits, both ionically and covalently bonded, are examined separately.
The results of the study provide evidence that heparin-bonded circuits result in improved clinical outcomes when compared to the identical nonheparin-bonded circuits. These improved clinical outcomes result in subsequent lower costs per patient with their use. However, differences are apparent in the significance and magnitude of these outcomes between ionically and covalently bonded circuits. Covalently bonded circuits provide a greater magnitude and significance of improvement in clinical outcomes than ionically bonded circuits. Total cost savings can be expected to be three times greater with covalently bonded circuits ($3231 versus $1068).
It was concluded that the choice regarding the use of a heparin-bonded circuits and the type of heparin-bonded circuit used has the potential to alter clinical outcomes and subsequent costs. Cost consideration cannot be ignored, but clinical benefits should be the main rationale for the choice of cardiopulmonary bypass circuit. This analysis provides evidence that clinical benefits and cost savings can both be derived from use of the same technology - covalently bonded circuits.
Get full access to this article
View all access options for this article.
References
1.
Gipe B , Harris S , Rosenberg M.A new method for direct cost analysis . Southwest Crit Care Assoc1995; 1: 1-16 .
2.
Drummond M , Stoddart G , Torrance G.Methods for evaluation of health care programs. New York: Oxford Medical Publications , 1987.
3.
Debois W , Brennan R , Wein E , Isom O , Gold J.Centrifugal pumping: the patient outcome benefits following coronary artery bypass surgery . J Extracorp Technol1995; 27: 77-80 .
4.
American Heart Association . Heart and stroke fact: 1996 statistical supplement. Dallas, TX: American Heart Association , 1996.
5.
Gibbon J Jr.Application of a mechanical heart and lung apparatus to cardiac surgery . Minn Med1954; 37: 171-185 .
Daniel S.Review on the multifactorial aspects of bioincompatibility in CPB . Perfusion1996; 11: 246-255 .
8.
Korn R , Fisher C , Livingston Eet al.The effects of Carmeda bioactive surface on human blood components during simulated extracorporeal circulation . J Thorac Cardiovasc Surg1996; 111: 1073-1084 .
9.
Edmunds L Jr.Blood surface interactions during cardiopulmonary bypass . J Card Surg1993; 8: 404-410 .
Svennig J , Froysaker T.Complement activation during extracorporeal circulation. In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator circuits . J Thorac Cardiovasc Surg1993; 106: 466-472 .
12.
Gorman J III , Edmunds L Jr.Blood anesthesia for cardiopulmonary bypass . J Card Surg1995; 10: 270-279 .
13.
Kirklin J , Westaby S , Blackstone Eet al.Complement and the damaging effects of cardiopulmonary bypass . J Thorac Cardiovasc Surg1983; 86: 845-857 .
14.
McLean J.The discovery of heparin . Circulation1959; 19: 75-78 .
15.
Best CH.Preparation of heparin and its use in the first clinical cases . Circulation1959; 19: 79-86 .
16.
Chargraff E , Olson K.Studies on the chemistry of blood coagulation. VI. Studies on the action of heparin and other anti-coagulant effect in vivo . J Biol Chem1938; 125: 671-676 .
17.
Aldea G , Doursounian P , O’Gara Pet al.Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study . Ann Thorac Surg1996; 62: 410-418 .
18.
Fosse E , Moen E , Johnson Eet al.Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass . Ann Thorac Surg1994; 58: 472-477 .
19.
Wendel H , Heller W , Hoffmeister H.Pathway of platelet protection in heparin-coated devices and its significance for cardiac surgery . Trans Soc Biomat1995; 21: 28-28 .
20.
Gu Y , van Oeveren W , van der Kamp K , Akkerman C , Boonstra P , Wildevuur CRH.Heparin-coating of extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass . Perfusion1991; 6: 221-225 .
21.
Pekna M , Hagman L , Halden Eet al.Complement activation during cardiopulmonary bypass: Effects of immobilized heparin . Ann Thorac Surg1994; 22: 421-424 .
22.
Gorman R , Ziats N , Gikakis Net al.Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass . J Thorac Cardiovasc Surg1996; 111: 1-12 .
23.
Ovrum E , Mollnes T , Fosse Eet al.Complement and granulocyte activation in two different types of heparinized extracorporeal circuits . J Thorac Cardiovasc Surg1995; 110: 1623-1632 .
24.
Jansen P , teVelthuis H , Huybregts Ret al.Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin coated circuits . J Thorac Cardiovasc Surg1995; 110: 829-834 .
25.
Boonstra P , Gu Y , Akkerman C , Haan J , Huyzen R , van Oeveren W.Heparin coating of an extracorporeal circuit partly improves hemostatis after cardiopulmonary bypass . J Thorac Cardiovasc Surg1994; 107: 289-292 .
26.
Ellwood P.Shattuck lecture - outcomes management: a technology of patient experience . N Engl J Med1988; 318: 1549-1556 .
27.
Donabedian A.The methods and findings of quality assessment and monitoring: an illustrated analysis. Volume 3. Ann Arbor, MI: Health Administration Press , 1985.
28.
Relman A.Assessment and accountability: the third revolution in medical care . N Engl J Med1988; 319: 1220-1222 .
29.
Eddy DM , Hasselblad V , Schachter R.Meta-analysis by the confidence profile method: the statistical synthesis of evidence. Boston, MA: Academic Press , 1992.
Edmunds L.Why cardiopulmonary bypass makes patients sick: strategies to control the blood-synthetic surface interface . Adv Cardiac Surg1995; 6: 131-167 .
32.
von Segessor L , Weiss B , Pasic Met al.Risk and benefits of low systemic heparinization during open heart operations . Ann Thorac Surg1994; 58: 391-398 .
33.
Borowiec J , Thelin S , Bagge L , van der Linden J , Thorno E , Hansson H.Heparin-coated cardiopulmonary bypass circuits in coronary artery surgery - a clinical study . J Extracorp Technol1990; 22: 86-90 .
34.
Borowiec J , Thelin S , Bagge L , Nilsson L , Venge P , Hansson H.Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass: a clinical study . J Thorac Cardiovasc Surg1992; 104: 642-647 .
35.
Jones D , Hill R , Vasilakis Aet al.Use of heparin-coated cardiopulmonary bypass . Ann Thorac Surg1993; 56: 566-568 .
36.
Ladowski J , Schatlein M , Peterson A , Deschner W , Matheis R , Ellenwood M.Clinical heparin coated cardiopulmonary bypass: reduction of systemic heparin requirements for redo cardiac surgery . ASAIO J1996; 42: 34-36 .
37.
Laub G , Clancy R , Chen Cet al.The impact of Carmeda bound cardiopulmonary bypass circuits on clinical outcome: a double-blind, randomized trial [Abstract]. In: Pathophysiology and techniques of cardiopulmonary bypass. San Diego : 1996.
38.
Sellevold OF , Berg TM , Rein KA , Levang OW , Iversen OJ , Bergh K.Heparin-coated circuit during cardiopulmonary bypass. A clinical study using closed circuit, centrifugal pump and reduced heparinization . Acta Anaesthesiol Scand1994; 38: 372-379 .
39.
Von Segesser L , Garcia E , Turina M.Low dose heparin versus full-dose heparin with high dose aprotinin during cardiopulmonary bypass . Tex Heart Inst J1993; 20: 28-32 .
40.
Wagner W , Johnson P , Thompson K , Marrone G.Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss . Ann Thorac Surg1994; 58: 734-741 .
41.
Moen O , Fosse E , Brockmeier Vet al.Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems . Ann Thorac Surg1995; 60: 1317-1323 .
42.
Knoch M , Kollen B , Dietrich G , Muller E , Mottaghy K , Lennartz H.Progress in veno-venous long-term bypass techniques for the treatment of ARDS . Int J Artif Organs1992; 15: 1013-1108 .
43.
Baufreton C , Le Besnerais P , Jansen P , Mazzucotelli J , Wildevur C , Loisance D.Clinical outcome after coronary surgery with heparin-coated extracorporeal circuits for cardiopulmonary bypass . Perfusion1996; 11: 437-443 .
44.
Rigby K , Crockett A , Silagy C.Can resource use be extracted from randomized controlled trials to calculate costs? A review of smoking cessation interventions in general practice . Int J Technol Assess Health Care1996; 12: 554-572 .
45.
Thacker S.Meta-analysis: a quantitative approach to research integration . J Am Med Assoc1988; 259: 1685-1689 .
46.
Sacks HS , Berrier J , Reitman D , Ancona-Berk VA , Chalmers T.Meta-analyses of randomized controlled trials . N Engl J Med1987; 316: 450-455 .
47.
Cooper H , Hedges L.The handbook of research synthesis. New York: Russell Sage Foundation , 1994.
48.
Borowiec J , Bylock A , van der Linden J , Thelin S.Heparin coating reduces blood cell adhesion to arterial filters during coronary bypass: a clinical study . Ann Thorac Surg1993; 55: 1540-1545 .
49.
Jansen P , Baufreton C , Le Besnerais P , Loisance D , Wildevuur C.Heparin-coated circuits and aprotinin prime for coronary artery bypass grafting . Ann Thorac Surg1996; 61: 1363-1366 .
50.
Jones D , Hill R , Vasilakis Aet al.Use of heparin-coated cardiopulmonary bypass . Ann Thorac Surg1993; 56: 566-568 .
51.
Muehrcke D , McCarthy P , Kottke-Marchant Ket al.Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial . J Thorac Cardiovasc Surg1996; 112: 472-483 .
52.
DerSimonian R , Laird N.Meta-analysis in clinical trials . Control Clin Trials1986; 7: 177-188 .
53.
Reeder GS.Angioplasty and the cost of myocardial revascularization: has its promise been fulfilled?Int J Cardiol1987; 15: 287-292 .
54.
Goldman L , Gordon D , Rifkind Bet al.Cost and health implications of cholesterol lowering . Circulation1992; 85: 1960-1968 .
55.
Federal Register, US Government Printing Office, 1996.
56.
O’Brien B , Rushby J.Outcome assessment in cardiovascular cost-benefit studies . Am Heart J1990; 119: 740-748 .
57.
Eisenberg JM.Clinical economics: a guide to the economic analysis of clinical practices . J Am Med Assoc1989; 262: 2879-2886 .
58.
Luce BR , Elixhauser A.Estimating costs in the economic evaluation of medical technologies . Int J Tech Assess in Health Care1990; 6: 57-75 .
59.
Mahoney CB.Pacing and outcomes: the economic implications. In: Geisler E , Heller O eds. Managing technology in health care. Norwell, MA: Kluwer Academic , 1996: 69-102.
60.
Aranki S , Adams D , Rizzo Ret al.Femoral veno-arterial extracorporeal life support with minimal or no heparin . Ann Thorac Surg1993; 56: 149-155 .
61.
Bennett J , Hill J , Long Wet al.Biocompatible circuits: an adjunct to non-cardiac extracorporeal cardiopulmonary support . J Extracorp Technol1992; 24: 6-11 .
62.
Bennett J , Parsons J.Heparin-free cardiopulmonary support, utilizing a Carmeda-coated circuit, for a patient with pulmonary hemorrhage and multiple trauma . American Society of Extracorporeal Technology Proceedings, 1993.
63.
Bianchi JJ , Swartz MT , Raithel SCet al.Initial clinical experience with centrifugal pumps coated with the Carmeda process . ASAIO J1992; 38: 143-146 .
64.
Biarent D , Bouton J M , Vanderrieviere J , DeMunter C , Desay H.Extracorporeal life support complications with heparin-coated circuits in children . Cardiol Young1995; 5: S1869-S1869 .
65.
Bindslev L , Ecklund J , Norlander Oet al.Treatment of acute respiratory failure by extracorporeal carbon dioxide elimination performed with a surface heparinized artificial lung . Anesthesiology1987; 67: 117-120 .
66.
Bindslev L.Adult ECMO performed with surface-heparinized equipment . ASAIO Trans1988; 34: 1009-1013 .
67.
Bindslev L , Bohm C , Jolin Aet al.Extracorporeal carbon dioxide removal performed with surface-heparinized equipment in patients with ARDS . Acta Anaesthesiol Scand Suppl1991; 95: 125-130 .
68.
Belboul A , Al-Khaja N , Gudmundsson Met al.The influence of heparin-coated and uncoated extracorporeal circuits on blood rheology during cardiac surgery . J Extracorp Technol1993; 25: 40-46 .
69.
Cardoso P , Yamazaki F , Keshaujee Set al.A reevaluation of heparin requirements for cardiopulmonary bypass . J Thorac Cardiovasc Surg1991; 101: 153-160 .
70.
Cederholm I , Johnson M , Carnstam B , Ljunghusen O , Olin C.Heparin coated circuit for cardiopulmonary bypass . 44th Annual Meeting of the Scandinavian Association for Thoracic Surgery, Orebro, Sweden, 1995; 37:
71.
Contino J , Follette D , Berkoff H , Pollock M , Bogren H , Wisner D.Use of Carmeda-coated femoral-femoral bypass during repair of traumatic aortic pseudoaneurysms . Arch Surg1994; 129: 933-937 .
72.
Dowling R , Brown M , Whittington R , Quinlan J , Armitage J.Clinical cardiopulmonary bypass without systemic anticoagulation . Ann Thorac Surg1993; 56: 1176-1178 .
73.
Elgue G , Blomback M , Olsson P , Riesenfeld J.The mechanism of coagulation inhibition on surfaces with end point immobilized heparin. Stockholm: The Department of Experimental Surgery, Karolinska Hospital , 1993.
74.
Fjalldal O , Torfason B , Onundarson PTet al.Prolonged total extracorporeal lung assistance without systemic heparinization . Acta Anaesthesiol Scand1993; 37: 115-120 .
75.
Golding L.Heparin-bonded extracorporeal life support systems . ASAIO J1996; 42: 16-18 .
76.
Gravlee G , Davis R , Utley J.Cardiopulmonary bypass: principles and practice. Baltimore, MD: Williams & Wilkins , 1993.
77.
Grossi E , Galloway A , Aguinaga Met al.Covalently bonded heparin bypass circuits reduce complement activation and cytokine production in pediatric patients. [Draft 1995.]
78.
Gu Y , van Oeveran W , Akkerman Cet al.Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass . Ann Thorac Surg1993; 55: 917-922 .
79.
Hatori N , Yoshizu H , Haga Yet al.Biocompatibility of heparin-coated membrane oxygenator during cardiopulmonary bypass . Artif Organs1994; 18: 904-910 .
80.
Heller W.Comparative studies on the haemo and biocompatibility of a heparin-coated system in aortocoronary bypass surgery . Cardiothorac Surg Symposium, 1995.
81.
Hollingsed M , Hill R , Wittig R , Murray G , Stullken E.Heparin coated cardiopulmonary bypass: a clinical case incorporating a standard cardiotomy . Perfusion1992; 7: 305-314 .
82.
Horikoshi S , Nakano M , Hashimoto Ket al.Alterations in coagulation, fibrinolysis and complement during cardiopulmonary bypass with a heparin-coated oxygenator . Artif Organs Today1994; 3: 239-252 .
83.
Iezzoni L ed. Risk adjustment for measuring health care outcomes. Ann Arbor, MI: Health Administration Press , 1994.
84.
Jolin A , Eden E , Berggren Het al.Management of a giant intracranial aneurysm using surface heparinized extracorporeal circulation and controlled deep hypothermic low flow perfusion. A case report . Acta Anaesthesiol Scand1993; 37: 756-760 .
85.
Kawahito K , Ino T , Adachi H , Ide H , Mizuhara A , Yamaguchi A.Heparin-coated percutaneous cardiopulmonary support for the treatment of circulatory collapse after cardiac surgery . ASAIO J1994; 40: 972-976 .
86.
Kawahito K , Ino T , Adachi Het al.Controlling the blood coagulation on the blood contacting surface of the assist devices - perfusion with heparin-coated equipment with low dose systemic heparinization . Jpn J Artif Organs1994; 23: 612-617 .
87.
Khuri SF , Valeri R , Losclazo Jet al.Heparin causes platelet dysfunction and indices of fibrinolysis before cardiopulmonary bypass . Ann Thorac Surg1995; 60: 1008-1014 .
88.
Koul B , Wetterberg T , Ohqvist G , Olsson P.Venovenous extracorporeal membrane oxygenation with heparin-coated system in adult respiratory distress syndrome . Scand J Thorac Cardiovasc Surg1991; 25: 199-206 .
89.
Larm O , Lins LE , Olsson P.An approach to anti-thrombosis by surface modification. Progress in Artificial Organs. Cleveland, OH: ISAIO Press , 1986.
90.
Larsson R , Larm O , Olsson P.The search for thromboresistance using immobilized heparin: blood in contact with natural and artificial surfaces . Ann NY Acad Sci1987; 516: 102-115 .
91.
Liu LS , Ito Y , Imanishi Y.Synthesis and anti-thrombogenicity of heparinized polyurethanes with intervening spacer chains of various kinds . Biomaterials1991; 12: 390-396 .
92.
Miyamoto Y , Nakano S , Takano H , Matsuda H.Beneficial effects of protease inhibitor (Nafamostat Mesilate) and heparin-coated circuit on hemostasis and inflammatory response during open heart surgery . Jpn J Artif Organs1994; 23: 606-611 .
93.
Moen O , Fosse E , Andersson C , Molness T , Hogasen K , Venge P.Heparin-coated surfaces reduce complement and granulocyte activation during CPB - a comparison of Bentley Duraflo II and the Carmeda Bioactive Surface (CBAS) . 44th Ann Meeting Scand Assoc Thoracic Surg, Orebro, Sweden, 1995; 1: 28-28 .
94.
Moines TE , Videm V , Gotze O , Harboe M , Oppermann M.Formation of C5a during cardiopulmonary bypass: inhibition by precoating with heparin . Ann Thorac Surg1991; 52: 92-97 .
95.
Mottaghy K , Oedekoven B , Schaich-Lester D , Pöppel K , Kupper W.Applications of surfaces with end point attached heparin to extracorporeal circulation with membrane lungs . ASAIO Trans1989; 35: 146-152 .
96.
Moulton M , Creswell L , Mackey M , Cox J , Rosenbloom M.Re-exploration for bleeding is a risk factor for adverse outcomes after cardiac operations . J Thorac Cardiovasc Surg1996; 11: 1037-1046 .
97.
Nilsson L , Peterson C , Venge P , Borowiec J , Thelin S.Eosinophil granule proteins in cardiopulmonary bypass with and without heparin coating . Ann Thorac Surg1995; 59: 713-716 .
98.
Nilsson U , Larm O , Nilsson B , Storm K , Elwing H , Nilsson Ekdahl K.Modification of the complement binding properties of polystyrene: effects of endpoint heparin attachment . Scand J Immunol1993; 37: 349-354 .
99.
Olsson P.Non-thrombogenic systems for extracorporeal gas exchange . Int J Artif Organs1993; 16.
100.
Olsson P , Larm O.Biologically active heparin coating in medical devices . lnt J Artif Organs1991; 14: 453-456 .
101.
Ovrum E.Eosinophil granulocyte activation and heparin-coated cardiopulmonary bypass [Letter] . Ann Thorac Surg1996; 61: 1038-1040 .
102.
Ovrum E , Mollnes T , Fosse Eet al.High and low heparin dose with heparin-coated cardiopulmonary bypass circuits: activation of complement and granulocytes . Ann Thorac Surg1995; 60: 1755-1761 .
103.
Peters J , Rademacher P , Kuntz Met al.Extracorporeal CO2-removal with a heparin coated artificial lung . Intensive Care Med1988; 14: 578-584 .
104.
Pradhan M , Fleming J , Nkere U , Arnold J , Wildevuur C , Taylor K.Clinical experience with heparin-coated cardiopulmonary bypass circuits . Perfusion1991; 6: 235-242 .
105.
Rossaint R , Slama K , Lewandowski Ket al.Extracorporeal lung assist with heparin-coated systems . Int J Artif Organs1992; 15: 29-34 .
106.
Shigemitsu O , Hadama T , Takasaki Het al.Biocompatibility of a heparin-bonded membrane oxygenator (Carmeda Maxima) during the first 90 minutes of cardiopulmonary bypass: clinical comparison with the conventional system . Artif Organs1994; 8: 936-941 .
107.
Shumway R , Lowe N , Wirth L , Riesenfeld J , Carmeda A , Olsson P.Functional characteristic determination of an immobilized bioactive heparin surface: a direct biological assay . Proc Am Acad Cardiovasc Perfusion1990; 11: 43-46 .
108.
Steinberg B , Grossi E , Schwartz D.Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass . Ann Thorac Surg1995; 60: 525-529 .
109.
Svenmarker S , Sandstrom E , Karlsson Tet al.Clinical benefit of the heparin-coated surface in cardiopulmonary bypass . 44th Annual Meeting of the Scandinavian Association for Thoracic Surgery, Orebro, Sweden, 1995.
110.
te Velthuis H , Jansen P , Hack C , Eijsman L , Wildevuur C.Specific complement inhibition with heparin-coated extracorporeal circuits . Ann Thorac Surg1996; 61: 1153-1157 .
111.
Thelin S , Bylock A , Bagge Let al.Heparin-coated cardiopulmonary bypass sets during surgery - a clinical study . J Extracorp Technol1990; 22: 6-6 .
112.
Tong D , Rolfs M , Hsu L.Evaluation of Duraflo II heparin imobilized cardiopulmonary bypass circuits . ASAIO Trans1990; 36: 654-656 .
113.
Utley J.Pathophysiology of cardiopulmonary bypass: current issues . J Card Surg1990; 5: 177-189 .
114.
van der Kamp K , van Oeveren W.Contact, coagulation and platelet interaction with heparin-treated equipment during heart surgery . Int J Artif Organs1993; 16: 836-842 .
115.
Videm V , Mollnes TE , Garred P , Svennevig JL.Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits . J Thorac Cardiovasc Surg1991; 101: 654-656 .
116.
Videm V , Svennevig J , Fosse E , Semb G , Osterud A , Molness T.Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations . J Thorac Cardiovasc Surg1992; 103: 806-813 .
117.
von Segesser LK , Weiss BM , Garcia E , Gallino AS , Turina M.Reduced blood loss and transfusion requirements with low systemic heparinization: preliminary clinical results in coronary artery revascularization . Eur J Cardiothorac Surg1990; 4: 639-643 .
118.
von Segesser LK , Weiss BM , Bisang B , Leskosek B , Turina M.Ventricular assist with heparin surface coated devices . ASAIO Trans1991; 67: H278-H279 .
119.
von Segesser LK , Weiss BM , Gallino Aet al.Superior hemodynamics in left heart bypass without systemic heparization . Eur J Cardiothorac Surg1990; 4: 3884-3889 .
120.
von Segesser LK , Lachat M , Gallino Aet al.Performance characteristics of centrifugal pumps with heparin surface coating . Thorac Cardiovasc Surg1990; 34: 224-228 .
121.
von Segesser LK , Wiss BM , Leskosek B , von Felten A , Pei P , Turina M.Experimental evaluation of heparin-coated cardiopulmonary bypass equipment with low systemic heparinization and high dose aprotinin . Thorac Cardiovasc Surg1991; 39: 251-256 .
122.
Weerwind P , Maessen J , van Tits Let al.Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass . J Thorac Cardiovasc Surg1995; 110: 1633-1641 .
123.
Weiss B , von Segesser L , Vetter W , Gautsch K , Pasch T.Heparin-coated left heart bypass: renal function and hormonal response . Int J Artif Organs1991; 14: 792-799 .
124.
Williams D , Dembitsky W.Prolonged extracorporeal support for ARDS using surface heparinised equipment . Chest1992; 102: 968-970 .
125.
Yamada H , Kudoh I , Hirose Y , Toyoshima M , Abe H , Kurahashi K.Heparin-coated circuits reduce the formation of TNF during cardiopulmonary bypass . Acta Anaesthesiol Scand1996; 40: 311-317 .
126.
Yamaguchi AMD , Ino TMD , Adachi HMDet al.Biocompatibility of heparin-coated circuits: alterations in cytokines, leukocyte and platelet activation during cardiopulmonary bypass in human . Jpn J Artif Organs1995; 24: 886-889 .
127.
Young J , Kisher C , Doty D.Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and appearance of fibrin monomer . Ann Thorac Surg1978; 26: 231-240 .
